Onco Actu du 29 juillet 2016

	2. Etiologie
Why working the night shift can pose a cancer risk [MIT News] In a study of mice, the MIT team found that two of the genes that control cells’ circadian rhythms also function as tumor suppressors.
	3.6 Prévention - Activité physique
An hour of exercise a day may compensate for an 'office lifestyle' [NHS Choices] The authors tried to account for what is called reverse causation – in this case that illness may have prevented people from being physically active – by including studies of apparently healthy adults. However they admit that this factor was not completely ruled out.
	4.11 Dép., diag. & prono. - Ovaire
Ovarian cancer test on horizon as scientists find earliest signs of disease [The Telegraph] Early treatment hugely improves the odds for patients, so early detection is essential. However, there is still a lot of work to be done because detecting SOX2 in the fallopian tubes is not an easy task.
	4.9 Dép., diag. & prono. - Sein
Updated Testing Guidelines Make More Women Eligible for Herceptin, yet Benefit Uncertain [Mayo Clinic] “Women who receive false positive results are not only exposed to the risks of HER2-directed therapies, but they also miss out on the treatments that could be effective against their cancer. That is counter to the goal of personalized medicine, which is to give the right drug to the right patient at the right time.”
	5. Traitements
NIH-led researchers develop software that could facilitate drug development [NIH] AptaTRACE is the first algorithm that uses the full scope of sequencing data from a large number of selection rounds to capture sequence and structure features of aptamers that bind to the target. Such information allows researchers to better understand why some molecules bind and others do not.
	5.2 Pharma
AbbVie Announces Initiation of Phase 3 Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma [AbbVie] Trial will study efficacy and safety of venetoclax in combination with bortezomib and dexamethasone in patients who are considered sensitive or naïve to proteasome inhibitors who have received 1 to 3 prior lines of therapy for multiple myeloma
	5.2.3 Pharma - économie
Earnings drop at Sanofi as it looks for a quick Medivation resolution [Pharmafile] Sanofi has published its earnings results for Q2, which show a fall in sales and profits as their diabetes division came under significant pricing scrutiny in the US. With established drugs lagging, a quick move for Medivation now appears a top priority for the French drugmaker.
AstraZeneca earnings hit by waning cholesterol drug sales [Reuters] Chief Executive Pascal Soriot believes AstraZeneca can become a major player in cancer treatment by developing drugs that bolster the immune system and others that disrupt DNA repair mechanisms used by tumor cells.
Bristol-Myers beats forecasts as hepatitis, cancer drugs deliver [Reuters] Yervoy appears to be rapidly losing share to Opdivo and Keytruda outside the United States.
U.S. biotech Celgene raises forecast as profit beats Street [Reuters] With Revlimid sales driven by new patient market share gains and longer duration of use, Celgene raised the full-year sales forecast for the medicine to $6.8 billion from $6.7 billion.
	5.4 Traitements - Economie
Make Drugmakers Pay: England’s Strategy for Cancer Medicines [Bloomberg] Under new rules, if the fund exceeds its 340 million-pound ($450 million) budget -- as it’s done in the past, overshooting by 37 percent in the final year before the revamp -- pharmaceutical companies will pick up the tab. And there’s no cap on that bill.
Controversial CDF revamp launches [PharmaTimes] Baroness Morgan, chief executive of the charity Breast Cancer Now, has said that the new CDF "will do next to nothing to solve the wider problems that are preventing NHS patients from accessing the best cancer drugs".
	6. Lutte contre les cancers
I’m an immigrant and a Muslim. And I’m here to cure cancer [STAT] According to a recent study published by George Mason University, immigrants make up 28 percent of all physicians and surgeons in this country.
NIH funds precision medicine research with a focus on health disparities [NIH] The approach of this new program, which focuses on health disparity populations, including racial and ethnic minorities, rural populations and low socioeconomic populations, shares the transformative vision represented by President Obama’s Precision Medicine Initiative.
	6.4 Médico-éco
Can the NHS really not afford second transplants for cancer patients like me? [The Guardian] The announcement has left me reeling. However healthy I might be right now, I know that my bone marrow is only one misstep away from needing a transplant again.
	6.9 Controverses
Stanford’s John Ioannidis On “underperforming Big Ideas” [Scope Blog] After several decades of substantial investment, the fundamental question is whether these big ideas have improved quality of life and life expectancy, by how much, for how many, and for whom. These are public dollars that should benefit the many, not the few.